Objective-To audit the outcome in patients with subarachnoid haemorrhage (SAH) after a change in management strategy. Methods-A retrospective analysis of patients with aneurysmal subarachnoid haemorrhage over a 20 month period (phase 1) was followed by a prospective analysis of patients presenting during the next 20 months (phase 2) in which a protocol driven management regime of immediate intravenous fluid resuscitation and earlier surgery was pursued. Patients in this phase were grouped into those receiving early (within four days of subarachnoid haemorrhage) and late (after four days of subarachnoid haemorrhage) surgery. In phase 1, 75 out of a total of 92 patients underwent surgery on (median) day 12. From phase 2, 109 patients out of a total of 129 underwent surgery on (median) day 4, 58 of which had their surgery within 4 days of the subarachnoid haemorrhage.
strategy.
Methods-A retrospective analysis of patients with aneurysmal subarachnoid haemorrhage over a 20 month period (phase 1) was followed by a prospective analysis of patients presenting during the next 20 months (phase 2) in which a protocol driven management regime of immediate intravenous fluid resuscitation and earlier surgery was pursued. Patients in this phase were grouped into those receiving early (within four days of subarachnoid haemorrhage) and late (after four days of subarachnoid haemorrhage) surgery. In phase 1, 75 out of a total of 92 patients underwent surgery on (median) day 12 . From phase 2, 109 patients out of a total of 129 underwent surgery on (median) day 4, 58 of which had their surgery within 4 days of the subarachnoid haemorrhage.
Patients in each phase/group were well matched for demographic features, site of aneurysm, and severity of subarachnoid haemorrhage. Results-The surgical morbidity and mortality were no different in the two phases (P < 0-92; x2 test). The management outcomes in the two phases of the study were also no different (P < 0.52).
However, there was a significant reduction in the rebleed rate in patients undergoing surgery within four days of the subarachnoid haemorrhage in phase 2 (P < 0-0001) with an associated trend towards reduced incidence of postoperative ischaemia (P = 0.06) and mortality (P = 0.11). Operating earlier in phase 2 of the trial resulted in a lower total hospital inpatient stay of 15*8 (95% days for survivors compared with 25 7 (95% CI 21-6-29.8) days in the late group (P < 0-00001; t test). Conclusions-surgical morbidity and mortality seemed independent of the timing of aneurysm surgery. Early surgery within four days was associated with a highly significant reduction in rebleed rate, and in the duration of total hospital inpatient stay.
(_ Neurol Neurosurg Psychiatry 1996;60:301-306) Keywords : Subarachnoid haemorrhage, timing of surgery, management outcome Without surgery, 60-70% of patients with aneurysmal subarachnoid haemorrhage die within one year of the initial ictus.'-3 About 30% of patients die within the first 48 hours as a result of the catastrophic effects of the initial haemorrhage, or from a further bleed. 45 In those who survive the initial insult, delayed cerebral ischaemia, and rebleeding are the main causes of morbidity and mortality in this condition.
The optimal management for aneurysmal subarachnoid haemorrhage remains controversial. Delayed surgery (>10 days after subarachnoid haemorrhage) is historically associated with a lower operative morbidity and mortality than early surgery, but is accompanied by a high incidence of rebleeding which is usually fatal.6-'0 In the multicentre British Aneurysm Nimodipine Trial the mean day of surgery was day 11-3 in the placebo and day 10-8 in the nimodipine treatment group, reflecting the preference for delayed surgery by many British neurosurgeons." Earlier surgery to secure the aneurysm neck reduces the occurrence of rebleeding but has traditionally been associated with increased operative morbidity. This may have been due to difficult operative conditions in patients with a swollen, non-autoregulating brain. Many reports of early surgery in subarachnoid haemorrhage exist in the medical literature'2-'9 teaching that if the consequences of delayed ischaemia can be suppressed by using hypervolaemic haemodilutional, hypertensive (HHH) therapy,20 a reduction of rebleeding can be translated into overall improved outcome. However, no difference in the management mortality between patients allocated to early or delayed surgery has been demonstrated.9 21 The incidence of delayed cerebral ischaemia varies between 13-5% and 44%.59 Cerebral vasospasm is believed to have a major role22 and reaches its highest incidence between days 7 and 10 after subarachnoid haemorrhage.f
The International Cooperative Study on the timing of aneurysm surgery showed that outcome was worse if surgery was performed during this period, a fact attributed to the effects of vasospasm.9 However, other factors may play a part in the pathogenesis of delayed ischaemia including hypotension, hypovolaemia, raised intracranial pressure, metabolic disturbances, and hypoxia.
Medical measures to counter the effects of cerebral ischaemia are available. Induced hypertension24-27 and maintenance of a high fluid input2-28 have been established in the prevention and treatment of delayed cerebral 301 2Whitfield, Moss, O'Hare, Smielewski, Pickard, Kirkpatrick ischaemia. The neuroprotective calcium channel antagonist nimodipine is also of proved efficacy in reducing the incidence of ischaemia after subarachnoid haemorrhage." Thus with additional improvements in neuroanaesthesia and operative microsurgical techniques, it is feasible that the morbidity associated with early surgery can be reduced.
As an initial approach to this hypothesis, we have conducted a retrospective review of the management and outcome in 92 patients with aneurysmal subarachnoid haemorrhage admitted to a regional neurosurgical unit during a 20 month period. We identified areas of concern and implemented a change in the management strategy with the objective of reducing delays in patient transfer, of improving perioperative medical resuscitation, and of reducing time to surgery. A subsequent prospective series of 129 patients was studied to establish the effect of these changes on the incidence of rebleeding, the development of postoperative ischaemia, duration of inpatient stay, and patient outcome after subarachnoid haemorrhage.
This study has appeared in abstract form. The total duration of hospital stay (15-8; 95% confidence interval (95% CI) 13-1-18-5 days) was shorter for survivors of early surgery in the second phase of the study compared with those of late surgery (25-7; 95% CI: 21 6-29-8 days), or those surviving from phase 1 (24-8; 95% CI 21-9-27-7 days). The differences between early and late groups were highly significant (P < 0-00001).
Discussion
The overall management outcome between phase 1 and phase 2 patients was very similar. Thus despite operating earlier during phase 2 of the study, morbidity was not increased. This contrasts with data from other studies,9 main and suggests that surgery can be performed late with acceptable morbidity and mortality in the Lase 2 early post-subarachnoid haemorrhage phase when modem medical and surgical techniques are followed. These include the routine use of prophylactic nimodipine, giving an appropritn of ate intravenous fluid regime perioperatively, rhage and attention to microsurgical techniques. ers of Historically, the risk of rebleeding has been unit declared maximal within the first 48 hours of hage. the initial ictus. 1 (20) Other in patients with subarachnoid haemorrhage from our catchment population. The tendency towards lower mortality and perioperative ischaemia in the early operated group of phase 2 patients needs further discussion. Despite a very similar distribution of severity of subarachnoid haemorrhage within each group, perioperative ischaemia and mortality seemed lower in patients operated on earlier although this did not reach significance. A disproportionate number of patients dying from the initial effects of the bleed in the early phase 2 group may be one reason why this did not translate into a significant reduction in mortality. In addition, two patients presenting with decompensating space occupying haematomas demanding urgent surgery, one of whom was severely disabled, were automatically placed in the early surgery group.
Perioperative ischaemia seemed to be reduced in phase 2 patients compared with those in phase 1, particularly in the early operated group although this just failed to reach significance. Because inaccuracies inherent within a mixed retrospective and prospective study are likely to be biased against phase 2 patients in that recording of perioperative ischaemia will not have been as accurate in the retrospective group, we are content that earlier surgery did not increase the morbidity from ischaemia. A larger prospective randomised trial will be required to determine whether this translates into significant reductions in morbidity and mortality.
A policy to transfer patients at an earlier stage after the subarachnoid haemorrhage resulted in an increased neurosurgical admission rate, from 58 to 74 patients a year in phase 2 of the audit. This may reflect a response to an "open door" policy for the early transfer of all patients with subarachnoid haemorrhage in phase 2. In phase 1 of the study, some patients may have died awaiting transfer to the neurosurgical unit. Surgery delayed beyond four days after the initial haemorrhage was associated with a high rebleed rate in phase 2 patients. As the median day of transfer during phase 1 was day 4, it is likely that the management outcome in phase 1 conceals significant mortality in patients while waiting in their referring hospitals, and also explains the higher incidence of phase 2 patients dying from the effects of the initial bleed.
The incidence of intraoperative aneurysm rupture was higher in phase 2 of the study, but similar in early and late treatment subgroups. The reasons for this are unclear, but may relate to the fragility of the recently formed thrombus in the early surgery patients. Further, there was an increased number of procedures performed by trainees in phase 2. However, intraoperative aneurysm rupture did not adversely affect morbidity and mortality in this series. Again the reasons for this are unclear. Adequate proximal vessel exposure and the use of temporary clips to control these feeding arteries allows the dissection to continue in a controlled fashion without necessarily resorting to "salvage" surgery and blind placement of clips. These techniques are being increasingly used and may help to account for the low incidence of unfavourable outcomes after inadvertent surgical rupture which has been noted by others. 39 The increase in neurosurgical workload in the second phase of the study has financial implications that should be set in the overall context of care from the initial ictus to final outcome. 40 The total duration of stay in the neurosurgical unit was significantly reduced in patients undergoing early surgery. We could identify no change in hospital related resources to account for this finding, except that of promoting earlier surgery. There had been no change in the level of patient support during recovery, and no increased pressure to discharge patients earlier. We are therefore confident in stating that earlier surgery has reduced overall hospital stay very significantly, and that this has been achieved without subjecting the patient to increased risks of morbidity. Although we have not conducted a detailed cost analysis, it is probable that the reduced hospital stay represents cost savings in the surgical treatment of aneurysmal subarachnoid haemorrhage.
In summary, despite the difficulties inherent in a mixed retrospective and prospective study the data obtained provide convincing evidence that, contrary to historical concern, early surgery for aneurysmal subarachnoid haemorrhage can be carried out safely. This approach also seems to reduce the time for patient recovery and inpatient stay. We present the data to stimulate other centres to prospectively analyse their management results in the treatment of subarachnoid haemorrhage.
